DexCom Under Legal Fire for Alleged Misleading Changes to Glucose Monitoring Devices

DexCom Faces Legal Scrutiny Over Allegations of Misleading Product Changes

DexCom, Inc. is currently under scrutiny as multiple law firms announce class action lawsuits concerning alleged misleading practices related to its glucose monitoring devices, the G6 and G7. The Gross Law Firm and Levi & Korsinsky, LLP have both issued notices to shareholders who purchased shares between January 8, 2024, and September 17, 2025. Allegations center on claims that DexCom failed to disclose unauthorized design changes that purportedly compromised the reliability of these devices, posing potential health risks to users. Reports indicate that the company overstated enhancements and downplayed associated risks, which may have led to increased regulatory scrutiny from entities such as the U.S. Food and Drug Administration (FDA).

The implications of these allegations are significant for DexCom, as they not only affect the company’s reputation but also expose it to heightened regulatory scrutiny and potential legal repercussions. Shareholders are encouraged to register for participation in the class action by December 26, 2025, with the option to seek lead plaintiff status, although this is not a requirement for recovery. The ongoing legal actions underscore a pressing concern about corporate accountability in the medical technology sector, where the reliability of health-related products is paramount.

Moreover, Halper Sadeh LLC is also investigating potential breaches of fiduciary duty by DexCom's executive officers and directors. This investigation highlights the broader implications of corporate governance and the need for transparency in the management of health technology companies. Long-term shareholders may have opportunities to advocate for corporate reforms or recover lost investments, emphasizing the importance of shareholder activism in enhancing corporate oversight and policies. Legal representation in these matters often operates on a contingency basis, allowing shareholders to pursue their rights without incurring upfront costs.

As these legal developments unfold, DexCom finds itself navigating a challenging landscape marked by potential legal liabilities and the need to maintain public trust in its products. The outcomes of these lawsuits and investigations could have significant ramifications for the company’s operations and its commitment to ensuring the safety and reliability of its glucose monitoring systems.